Safety & Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients

See also
Status	Clinical Trial	Phase
Completed	`NCT01228734` - A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients	Phase 3
Completed	`NCT05178745` - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Completed	`NCT01591421` - P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.	Phase 1/Phase 2
Withdrawn	`NCT05412706` - Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy	Phase 2
Withdrawn	`NCT04430985` - FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer	Phase 2
Withdrawn	`NCT03182894` - Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT05725200` - Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer	Phase 2
Terminated	`NCT03176264` - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer	Phase 1
Completed	`NCT04866290` - HepaSphere™ Microspheres Prospective Registry
Not yet recruiting	`NCT06425133` - Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers	Phase 2
Not yet recruiting	`NCT05531045` - 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
Withdrawn	`NCT03982173` - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors	Phase 2
Completed	`NCT02906059` - Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer	Phase 1
Active, not recruiting	`NCT02575378` - Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer	Phase 4
Withdrawn	`NCT02535988` - Abscopal Effect for Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT02848807` - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life	N/A
Active, not recruiting	`NCT02077868` - Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment	Phase 3
Completed	`NCT02414009` - Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients	Phase 2
Active, not recruiting	`NCT01949194` - Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers	Phase 2
Withdrawn	`NCT01915472` - A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer	Phase 2

NCT number	NCT03405272
Study type	Interventional
Source	Sinocelltech Ltd.
Contact	xiaoling yang
Phone	0086-10-58628288
Email	xiaoling_yang@sinocelltech.com
Status	Not yet recruiting
Phase	Phase 2
Start date	February 12, 2018
Completion date	December 1, 2019

Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms